Oxford Cannabinoid Technologies Holdings plc announced the appointment of Dr. Tim Corn as the Company's new Chief Medical Officer effective immediately. Dr. Corn is an independent pharmaceuticals consultant who has held senior positions in both large and small pharma organisations. He is currently CMO at Nodenza Inc. and Medical Adviser to Confo Therapeutics SA, which recently announced a global licensing deal with Eli Lilly and Company for the clinical stage peripheral pain candidate CFTX-1554 and back-up compounds.

He also serves as a non-executive director on the Board of Physiomics plc. He was formerly Chief Medical Officer International at Jazz Pharmaceuticals plc and CMO at venture-backed companies EUSA Pharma Inc, acquired by Jazz Pharmaceuticals plc in 2012, and Zeneus Pharma Ltd, acquired by Cephalon Inc. in 2005. Dr Corn has also played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe and is the author of more than forty scientific publications.

He was elected a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists. Dr. Corn will oversee the Company's clinical research and development activities as well as providing expert medical guidance and advice to the team.